首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   178319篇
  免费   14056篇
  国内免费   3689篇
耳鼻咽喉   1405篇
儿科学   2541篇
妇产科学   3116篇
基础医学   23194篇
口腔科学   3346篇
临床医学   12427篇
内科学   22163篇
皮肤病学   2250篇
神经病学   11922篇
特种医学   6445篇
外国民族医学   1篇
外科学   14470篇
综合类   24436篇
一般理论   8篇
预防医学   14446篇
眼科学   2173篇
药学   25753篇
  72篇
中国医学   13649篇
肿瘤学   12247篇
  2023年   2137篇
  2022年   3034篇
  2021年   5875篇
  2020年   6582篇
  2019年   7598篇
  2018年   5875篇
  2017年   6609篇
  2016年   6459篇
  2015年   5872篇
  2014年   6875篇
  2013年   10876篇
  2012年   8930篇
  2011年   10909篇
  2010年   6984篇
  2009年   7149篇
  2008年   8594篇
  2007年   9443篇
  2006年   9008篇
  2005年   8355篇
  2004年   7157篇
  2003年   6472篇
  2002年   5082篇
  2001年   4625篇
  2000年   3880篇
  1999年   3308篇
  1998年   2470篇
  1997年   2473篇
  1996年   2273篇
  1995年   2104篇
  1994年   2060篇
  1993年   1707篇
  1992年   1582篇
  1991年   1473篇
  1990年   1280篇
  1989年   1042篇
  1988年   1011篇
  1987年   912篇
  1986年   830篇
  1985年   1210篇
  1984年   966篇
  1983年   729篇
  1982年   756篇
  1981年   617篇
  1980年   598篇
  1979年   479篇
  1978年   298篇
  1977年   260篇
  1976年   243篇
  1975年   188篇
  1974年   144篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data.  相似文献   
2.
3.
4.
5.
6.
7.
8.
9.
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment.  相似文献   
10.
Adiponectin is the major adipocytes-secreted protein involved in obesity-related breast cancer growth and progression. We proved that adiponectin promotes proliferation in ERα-positive breast cancer cells, through ERα transactivation and the recruitment of LKB1 as ERα-coactivator. Here, we showed that adiponectin-mediated ERα transactivation enhances E-cadherin expression. Thus, we investigated the molecular mechanism through which ERα/LKB1 complex may modulate the expression of E-cadherin, influencing tumor growth, progression and distant metastasis. We demonstrated that adiponectin increases E-cadherin expression in ERα-positive 2D and higher extent in 3D cultures. This occurs through a direct activation of E-cadherin gene promoter by ERα/LKB1-complex. The impact of E-cadherin on ERα-positive breast cancer cell proliferation comes from the evidence that in the presence of E-cadherin siRNA the proliferative effects of adiponectin is no longer noticeable. Since E-cadherin connects cell polarity and growth, we investigated if the adiponectin-enhanced E-cadherin expression could influence the localization of proteins cooperating in cell polarity, such as LKB1 and Cdc42. Surprisingly, immunofluorescence showed that, in adiponectin-treated MCF-7 cells, LKB1 and Cdc42 mostly colocalize in the nucleus, impairing their cytosolic cooperation in maintaining cell polarity. The orthotopic implantation of MCF-7 cells revealed an enhanced E-cadherin-mediated breast cancer growth induced by adiponectin. Moreover, tail vein injection of MCF-7 cells showed a higher metastatic burden in the lungs of mice receiving adiponectin-treated cells compared to control. From these findings it emerges that adiponectin treatment enhances E-cadherin expression, alters cell polarity and stimulates ERα-positive breast cancer cell growth in vitro and in vivo, sustaining higher distant metastatic burden.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号